Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | TET3 | O43151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.33 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.33 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16102404 | 0.86 | TET3 (0.41) | JAK3BTKTET3KMT2AFBXL19 | |
| SCHEMBL22600556 | 0.80 | CYP2D6 (0.38) | JAK3BTKTET3KMT2AFBXL19 | |
| SCHEMBL25809391 | 0.78 | L3MBTL3 (0.45) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL29724137 | 0.77 | GRM5 (0.38) | JAK3BTKTET3KMT2AFBXL19 | |
| SCHEMBL29724127 | 0.77 | TET3 (0.38) | JAK3BTKTET3KMT2AFBXL19 | |
| SCHEMBL19909730 | 0.76 | NAMPT (0.31) | NAMPT | |
| SCHEMBL16127680 | 0.75 | JAK3 (0.42) | JAK3BTKTET3KMT2AFBXL19 | |
| SCHEMBL22753531 | 0.75 | TET3 (0.38) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL30059414 | 0.75 | NAMPT (0.36) | NAMPT | |
| SCHEMBL24448687 | 0.73 | JAK3 (0.38) | JAK3BTKTET3KMT2AFBXL19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | Karyopharm Therapeutics Inc. (US) | 2019-02-12 | — | — | US | claimed |
| EP-4587435-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024056077-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-21 | — | — | WO | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2011114275-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | XPO1, XPA, ERCC2 | JAK3 4560/4885BTK 4768/4885TET3 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.